瑞银发表研究报告指，泰格医药(03347.HK) 次季收入按年跌0.7%至16.9亿元人民币(下同)，跌幅较首季跌5.8%有所改窄，惟逊于该行及市场预期；净利润按年降15.5%至2.18亿元，相对首季按年跌幅为29.6%，同样逊于该行及市场预期。
该行表示，泰格医药维持其全年指引，预计收入将按年增长高个位数，同时期望毛利率可按季回升，经常性净利润率有望改善。考虑到首季新订单增长，公司将全年相关预测上调至约15%，而此前预测则为逾10%。此外，公司预计今年的净经营现金流达约10亿元人民币，并计划通过派息或股票回购来增强股东回报。
该行下调集团2025至27年每股盈测分别9%、4.3%及0.1%，目标价由49.1元上调至56.3元，重申“买入”评级。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.